Table 2.
Metabolic characteristics of patients with type 2 diabetes and nonalcoholic fatty liver disease by liraglutide use.
| Characteristic | Before | After | p |
|---|---|---|---|
| General and biochemical markers | 49 | 49 | |
| BMI, kg/m2 | 28.76 (26.93, 30.9) | 27.72 (26.79, 30.85) | 0.011 |
| FBG, mmol/L | 9.99 (7.49, 12.88) | 8.13 (6.57, 11.30) | 0.496 |
| HbA1c, % | 10 (8.57, 11.4) | 8.7 (7.8, 9.55) | 0.009 |
| LDL, mmol/L | 2.68 ± 0.87 | 2.34 ± 0.80 | 0.433 |
| HDL, mmol/L | 0.84 (0.72, 0.98) | 0.96 (0.81, 1.088) | 0.023 |
| ALT, IU/L | 25 (18, 42) | 24 (15, 37) | 0.332 |
| AST, IU/L | 21 (15, 33) | 18 (16.26.2) | 0.210 |
| ALP, IU/L | 81.41 ± 30.19 | 77.33 ± 15.5 | 0.244 |
| r-GT, IU/L | 32.35 (21.25, 67.78) | 34.6 (19, 42) | 0.856 |
| eGFR, ml/min/1.73 m2 | 115.23 ± 51.74 | 109.96 ± 31.74 | 0.102 |
| FT3, pmol/L | 4.76 (4.34, 5.28) | 4.51 (4.18, 5.11) | 0.826 |
| FT4, pmol/L | 14.17 (12.49, 16.07) | 13.24 (11.92, 14.47) | 0.975 |
| TSH, mIU/L | 1.94 (1.12, 2.95) | 1.46 (0.89, 2.04) | 0.019 |
|
| |||
| Use of hypoglycemic drugs | |||
| Insulin (N, %) | 21 (42.9%) | 18 (36.7%) | 0.536 |
| Metformin (N, %) | 29 (59.2%) | 34 (69.4%) | 0.292 |
| Thiazolidinediones (N, %) | 3 (6.1%) | 1 (2.0%) | 0.617 |
| Sulfonylureas/glinides (N, %) | 3 (6.1%) | 1 (2.0%) | 0.617 |
| Glucosidase inhibitors | 11 (22.4%) | 7 (14.3%) | 0.545 |
| SGLT2 inhibitors | 29 (59.2%) | 27 (55.1%) | 0.683 |